The race to develop a new class of lung-cancer medicines is pitting one of the world’s biggest drugmakers against a five-year-old startup. AstraZeneca Plc (AZN), the U.K.’s second-largest pharmaceutical company, and Clovis Oncology Inc. (CLVS) of Boulder, Colorado, both intend to seek approval from regulators next year. Both drugs, which target a form of the […]